Immunomedics, Inc.

NASDAQ: IMMU
$41.32
-$0.98 (-2.3%)
Closing price July 10, 2020
BofA Securities has made huge changes to its US 1 list of top stocks to buy. These five additions should fare well in the second half of 2020.
Immunomedics shares jumped on Thursday after the company announced a key update from the FDA for its breast cancer treatment Trodelvy.
Tuesday's top analyst upgrades and downgrades included BHP, Electronic Arts, Gilead Sciences, Immunomedics, KeyCorp, Peloton Interactive, Shopify, Sunnova Energy, Take-Two Interactive and Walt Disney.
Immunomedics shares soared on Monday after the announcements that a late-stage breast cancer study was halted early and a new chief executive officer was named.
Immunomedics shares made a handy gain on Thursday after the company announced that the FDA has accepted its Biologics License Application for its breast cancer treatment.
Here are five health-care-related stocks that recently saw their 50-day moving average cross above the 200-day average, a golden cross.
Immunomedics shares dropped sharply on Monday after the firm presented interim data from its midstage bladder cancer study at the European Society for Medical Oncology (ESMO) Annual Congress in...
The top analyst upgrades, downgrades and initiations seen on Monday included Alector, Bed Bath & Beyond, Dillard's, Foot Locker, Hasbro, Kraft Heinz, Vale, Xilinx and Zoetis.
Immunomedics, Signet Jewelry, Nautilus, and Lexicon Pharmaceuticals had all posted new 52-week lows by noon Friday.
Immunomedics shares were crushed on Friday after the firm received disappointing news from the FDA on its breast cancer treatment.
The top analyst upgrades, downgrades and other research calls from Monday include Ctrip.com, Goldman Sachs, Johnson & Johnson, Medtronic, Morgan Stanley, Yelp and Yum China.
Here are four biotech stocks for which the team of analysts at Jefferies, and analysts at other firms, see big upside potential from upcoming near-term drug study catalysts.
Immunomedics watched its shares make a massive gain on Friday after the company announced the termination of its licensing deal with Seattle Genetics.
The health care sector was in trouble over the past year, under fire from congressional hearings and politicians on the campaign trail. At first 2017 seemed like it could be different for this...
In the week of October 7, there were multiple analyst calls for stocks to buy that were trading under $10 per share, including Petrobras and Brocade Communications.